The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades

被引:39
|
作者
Romero-Pinel, Lucia [1 ]
Bau, Laura [1 ]
Matas, Elisabet [1 ]
Leon, Isabel [1 ]
Munoz-Vendrell, Albert [1 ]
Arroyo, Pablo [1 ]
Masuet-Aumatell, Cristina [2 ]
Martinez-Yelamos, Antonio [1 ,3 ]
Martinez-Yelamos, Sergio [1 ,3 ]
机构
[1] Hosp Univ Bellvitge IDIBELL, Multiple Sclerosis Unit, Dept Neurol, Barcelona, Spain
[2] Hosp Univ Bellvitge IDIBELL, Dept Epidemiol & Prevent Med, Barcelona, Spain
[3] Univ Barcelona UB, Fac Med & Ciencies Salut, Dept Ciencies Clin, Barcelona, Spain
关键词
Age at onset; Disease course; Epidemiology; Multiple sclerosis; Relapsing-remitting; EPSTEIN-BARR-VIRUS; DIAGNOSTIC-CRITERIA; VITAMIN-D; PREVALENCE; RISK; ANTICIPATION; INFECTION; SMOKING; OBESITY;
D O I
10.1016/j.msard.2022.104103
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) most commonly experience their first symptoms between 20 and 40 years of age. The objective of this study was to investigate how the age at which the first symptoms of RRMS occur has changed over the past decades. Methods: Patients who were followed up in our unit after an initial diagnosis of RRMS using the Poser or McDonald criteria and who experienced their first symptoms between January 1970 and December 2019 were included in the study. The cohort was divided into five groups according to the decade in which the first symptoms appeared. The age at disease onset was compared across decades. Changes in age were also deter-mined after excluding patients with early-onset disease (< 18 years of age) and those with late-onset disease (> 50 years of age) to avoid bias. Results: The cohort included 1,622 patients with RRMS, 67.6% of whom were women. Among them, 5.9% and 4% had early-onset and late-onset disease, respectively. The mean age +/- standard deviation at onset was 31.11 +/- 9.82 years, with no differences between men and women. The mean ages at onset were 23.79 +/- 10.19 years between 1970 and 1979, 27.86 +/- 9.22 years between 1980 and 1989, 30.07 +/- 9.32 years between 1990 and 1999, 32.12 +/- 9.47 between 2000 and 2009, and 34.28 +/- 9.83 years between 2010 and 2019. The ages at disease onset were progressively higher in the later decades; this trend was statistically significant (p < 0.001), with a Pearson linear correlation coefficient R of 0.264 and R2 of 0.070 (p < 0.001). The results were similar when analysing men and women separately. We conducted an analysis of 1,460 patients (mean age at onset: 31.10 +/- 7.99 years), after excluding patients with early-onset and late-onset disease. In this specific subgroup, the mean ages at disease onset were 28.38 +/- 8.17 years between 1970 and 1979, 29.22 +/- 7.51 years between 1980 and 1989, 30.06 +/- 8.02 years between 1990 and 1999, 31.46 +/- 7.77 years between 2000 and 2009, and 33.37 +/- 7.97 years between 2010 and 2019. The trend was also statistically significant (p < 0.001), with a Pearson linear correlation coefficient R of 0.193 and R2 of 0.037 (p < 0.001). Conclusion: Our data showed that the age at RRMS onset has increased over the past decades.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
    Alroughani, Raed
    Van Wijmeersch, Bart
    Al Khaboori, Jabber
    Alsharoqi, Isa Ahmed
    Ahmed, Samar F.
    Hassan, Ali
    Inshasi, Jihad
    Krieger, Derk W.
    Shakra, Mustafa
    Shatila, Ahmed Osman
    Szolics, Miklos
    Khallaf, Mohamed
    Ezzat, Aly
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [22] Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis
    Koudriavtseva, Tatiana
    Stefanile, Annunziata
    Fiorelli, Marco
    Lapucci, Caterina
    Lorenzano, Svetlana
    Zannino, Silvana
    Conti, Laura
    D'Agosto, Giovanna
    Pimpinelli, Fulvia
    Di Domenico, Enea Gino
    Mandoj, Chiara
    Giannarelli, Diana
    Donzelli, Sara
    Blandino, Giovanni
    Salvetti, Marco
    Inglese, Matilde
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [23] Development of laquinimod for relapsing-remitting multiple sclerosis
    Jeffery, Douglas R.
    FUTURE NEUROLOGY, 2008, 3 (06) : 641 - 648
  • [24] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [25] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [26] Cognitive Impairment In Relapsing-Remitting Multiple Sclerosis
    Topcular, Baris
    Ozcan, M. Emin
    Kurt, Elif
    Kuscu, Demet Yandim
    Icen, Nilufer Kale
    Sutlas, Pakize Nevin
    Kirbas, Dursun
    Bingol, Ayhan
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2012, 49 (03): : 178 - 182
  • [27] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [28] PROGNOSIS OF DISABILITY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Somilo, O., V
    Kalbus, O., I
    Makarov, S. O.
    Sorokin, A. V.
    Shastun, N. P.
    WORLD OF MEDICINE AND BIOLOGY, 2023, 84 (02): : 147 - 152
  • [29] Executive functions in relapsing-remitting multiple sclerosis
    Elosua, M. Rosa
    Villadangos, Noelia
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,
  • [30] Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
    Buscarinu, M. C.
    Romano, S.
    Mechelli, R.
    Umeton, R. Pizzolato
    Ferraldeschi, M.
    Fornasiero, A.
    Renie, R.
    Cerasoli, B.
    Morena, E.
    Romano, C.
    Loizzo, N. D.
    Umeton, R.
    Salvetti, M.
    Ristori, G.
    NEUROTHERAPEUTICS, 2018, 15 (01) : 68 - 74